<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01367483</url>
  </required_header>
  <id_info>
    <org_study_id>MNTX 102</org_study_id>
    <nct_id>NCT01367483</nct_id>
  </id_info>
  <brief_title>Study of the Pharmacokinetics of Intravenous Administered 14C-MNTX</brief_title>
  <official_title>An Open-Label, Phase I, Single Dose Study of the Pharmacokinetics, Mass Balance and Disposition of Intravenously Administered 14C-Methylnaltrexone in Normal, Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valeant Pharmaceuticals International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valeant Pharmaceuticals International, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, radiotracer study, to be conducted in healthy, normal, male
      volunteers. It will entail intravenous administration of a single dose of 14C-MNTX,
      collection of excretions, and periodic drawing of blood samples. Exhaled 14CO2 will also be
      sampled as a measure of the extent of possible metabolic MNTX demethylation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma and Whole Blood Concentration (Cmax) of IV MNTX</measure>
    <time_frame>5.5 days</time_frame>
    <description>To study the pharmacokinetics of MNTX following a single IV dose of 14C-MNTX in normal, healthy volunteers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum (Tmax) in Plasma and Whole Blood Concentration of IV MNTX</measure>
    <time_frame>5.5 Days</time_frame>
    <description>To study the pharmacokinetics of MNTX following a single IV dose of 14C-MNTX in normal, healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of IV MNTX</measure>
    <time_frame>5.5 days</time_frame>
    <description>To study the pharmacokinetics of MNTX following a single IV dose of 14C-MNTX in normal, healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of IV MNTX</measure>
    <time_frame>5.5 days</time_frame>
    <description>To study the pharmacokinetics of MNTX following a single IV dose of 14C-MNTX in normal, healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution of IV MNTX</measure>
    <time_frame>5.5 days</time_frame>
    <description>To study the pharmacokinetics of MNTX following a single IV dose of 14C-MNTX in normal, healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Clearance of IV MNTX</measure>
    <time_frame>5.5 days</time_frame>
    <description>To study the pharmacokinetics of MNTX following a single IV dose of 14C-MNTX in normal, healthy volunteers.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Healthy Male Volunteers</condition>
  <arm_group>
    <arm_group_label>Arm1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MNTX active treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV methylnaltrexone (MNTX)</intervention_name>
    <arm_group_label>Arm1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males between 18-45

          2. Subject weight between 70 and 90 kg

          3. In good physical health, with no evidence at screening of acute or chronic disease
             likely to affect the investigation

        Exclusion Criteria:

          1. History or evidence of cardiovascular, gastrointestinal, hepatic, neurological,
             pulmonary, renal, or other significant chronic condition.

          2. Consumption of barbiturates or other inducers or inhibitors of CYP450 isoforms

          3. History of or predisposition to erratic or abnormal bowel function.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tage Ramakrishna, MD</last_name>
    <role>Study Director</role>
    <affiliation>Progenics Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Progenics Pharmaceuticals, Inc.</name>
      <address>
        <city>Tarrytown</city>
        <state>New York</state>
        <zip>10591</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2011</study_first_submitted>
  <study_first_submitted_qc>June 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2011</study_first_posted>
  <last_update_submitted>July 17, 2011</last_update_submitted>
  <last_update_submitted_qc>July 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Tage Ramakrishna, MD</name_title>
    <organization>Progenics Pharmaceuticals</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylnaltrexone</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

